Analysis of gene profiles involved in the enhancement of all-trans retinoic acid-induced HL-60 cell differentiation by sesquiterpene lactones identifies asparagine synthetase as a novel target for differentiation-inducing therapy

Song,Ju Han; Kim,Seung Hyun; Cho,Kyung-Min; Hwang,Seung Yong; Kim,Hyeoung-Joon; Kim,Tae Sung

doi:10.3892/ijo.2013.2241

Analysis of gene profiles involved in the enhancement of all-trans retinoic acid-induced HL-60 cell differentiation by sesquiterpene lactones identifies asparagine synthetase as a novel target for differentiation-inducing therapy

Authors:
- Ju Han Song
- Seung Hyun Kim
- Kyung-Min Cho
- Seung Yong Hwang
- Hyeoung-Joon Kim
- Tae Sung Kim
View Affiliations

Affiliations: Department of Life Sciences, College of Life Sciences and Biotechnology, Korea University, Seoul 136-701, Republic of Korea, Division of Molecular and Life Science and GenoCheck Co. Ltd., Hanyang University, Ansan 426-791, Republic of Korea, Genome Research Center for Hematopoietic Diseases, Chonnam National University Hwasun Hospital, Hwasun 519-809, Republic of Korea
Published online on: December 31, 2013 https://doi.org/10.3892/ijo.2013.2241
Pages: 970-976

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

All-trans retinoic acid (ATRA) is one of the most useful drugs in the treatment for acute promyelocytic leukemia (APL), but its adverse effects, which include drug resistance and hypercalcemia are obstacles to achieving complete remission. Our previous study showed that some sesquiterpene lactones (STLs), i.e., helenalin (HE) and parthenolide (PA) but not sclareolide (SC), enhance ATRA-induced differentiation of HL-60 APL cells with no unexpected effects, but the precise mechanism on underlying this synergism is not yet fully understood. In this study, we investigated the distinctive transcriptional profile of cells treated with effective STL compounds, which were identified by comparing the profile with that of cells treated with SC. Genome-wide approaches using cDNA microarrays showed that co-treatment with the differentiation-enhancing STLs HE and PA maximized the transcriptional variation regulated by the suboptimal concentration of ATRA in HL-60 cells. Of the genes of interest, asparagine synthetase was remarkably downregulated by ATRA co-treated with either HE or PA, but not with SC. In an additional analysis for the role of asparagine synthetase, ATRA-mediated HL-60 cell differentiation was enhanced when asparagine in the culture media was depleted by an addition of L-asparaginase, indicating that downregulation of asparagine synthetase gene expression may be involved in the enhanced cell differentiation by STL compounds. These results provide useful insight into differentiation-inducing therapy in the treatment of leukemia.

View Figures

View References

1.	Breitman TR, Selonick SE and Collins SJ: Induction of differentiation of the human promyelocytic leukemia cell line (HL-60) by retinoic acid. Proc Natl Acad Sci USA. 77:2936–2940. 1980. View Article : Google Scholar
2.	Breitman TR, Collins SJ and Keene BR: Terminal differentiation of human promyelocytic leukemic cells in primary culture in response to retinoic acid. Blood. 57:1000–1004. 1981.PubMed/NCBI
3.	Flynn PJ, Miller WJ, Weisdorf DJ, Arthur DC, Brunning R and Branda RF: Retinoic acid treatment of acute promyelocytic leukemia: in vitro and in vivo observations. Blood. 62:1211–1217. 1983.PubMed/NCBI
4.	Huang ME, Ye YC, Chen SR, et al: Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood. 72:567–572. 1988.
5.	Collins SJ, Robertson KA and Mueller L: Retinoic acid-induced granulocytic differentiation of HL-60 myeloid leukemia cells is mediated directly through the retinoic acid receptor (RAR-alpha). Mol Cell Biol. 10:2154–2163. 1990.PubMed/NCBI
6.	Duprez E, Wagner K, Koch H and Tenen DG: C/EBPbeta: a major PML-RARA-responsive gene in retinoic acid-induced differentiation of APL cells. EMBO J. 22:5806–5816. 2003. View Article : Google Scholar : PubMed/NCBI
7.	Matikainen S, Ronni T, Hurme M, Pine R and Julkunen I: Retinoic acid activates interferon regulatory factor-1 gene expression in myeloid cells. Blood. 88:114–123. 1996.PubMed/NCBI
8.	Bennett MT, Sirrs S, Yeung JK and Smith CA: Hypercalcemia due to all trans retinoic acid in the treatment of acute promyelocytic leukemia potentiated by voriconazole. Leuk Lymphoma. 46:1829–1831. 2005.
9.	Imaizumi M, Suzuki H, Yoshinari M, et al: Mutations in the E-domain of RAR portion of the PML/RAR chimeric gene may confer clinical resistance to all-trans retinoic acid in acute promyelocytic leukemia. Blood. 92:374–382. 1998.PubMed/NCBI
10.	Montesinos P, Bergua JM, Vellenga E, et al: Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors. Blood. 113:775–783. 2009. View Article : Google Scholar : PubMed/NCBI
11.	Shao W, Benedetti L, Lamph WW, Nervi C and Miller WH Jr: A retinoid-resistant acute promyelocytic leukemia subclone expresses a dominant negative PML-RAR alpha mutation. Blood. 89:4282–4289. 1997.PubMed/NCBI
12.	Lengfelder E, Saussele S, Weisser A, Büchner T and Hehlmann R: Treatment concepts of acute promyelocytic leukemia. Crit Rev Oncol Hematol. 56:261–274. 2005. View Article : Google Scholar
13.	Hehner SP, Hofmann TG, Dröge W and Schmitz ML: The antiinflammatory sesquiterpene lactone parthenolide inhibits NF-kappa B by targeting the I kappa B kinase complex. J Immunol. 163:5617–5623. 1999.PubMed/NCBI
14.	Sobota R, Szwed M, Kasza A, Bugno M and Kordula T: Parthenolide inhibits activation of signal transducers and activators of transcription (STATs) induced by cytokines of the IL-6 family. Biochem Biophys Res Commun. 267:329–333. 2000. View Article : Google Scholar : PubMed/NCBI
15.	Oka D, Nishimura K, Shiba M, et al: Sesquiterpene lactone parthenolide suppresses tumor growth in a xenograft model of renal cell carcinoma by inhibiting the activation of NF-kappaB. Int J Cancer. 120:2576–2581. 2007. View Article : Google Scholar : PubMed/NCBI
16.	Sohma I, Fujiwara Y, Sugita Y, et al: Parthenolide, an NF-κB inhibitor, suppresses tumor growth and enhances response to chemotherapy in gastric cancer. Cancer Genomics Proteomics. 8:39–47. 2011.
17.	Hoffmann R, von Schwarzenberg K, López-Antón N, Rudy A, Wanner G, Dirsch VM and Vollmar AM: Helenalin bypasses Bcl-2-mediated cell death resistance by inhibiting NF-κB and promoting reactive oxygen species generation. Biochem Pharmacol. 82:453–463. 2011.PubMed/NCBI
18.	Kassuya CA, Cremoneze A, Barros LF, et al: Antipyretic and anti-inflammatory properties of the ethanolic extract, dichloromethane fraction and costunolide from Magnolia ovata (Magnoliaceae). J Ethnopharmacol. 124:369–376. 2009. View Article : Google Scholar : PubMed/NCBI
19.	Lyss G, Knorre A, Schmidt TJ, Pahl HL and Merfort I: The anti-inflammatory sesquiterpene lactone helenalin inhibits the transcription factor NF-kappaB by directly targeting p65. J Biol Chem. 273:33508–33516. 1998. View Article : Google Scholar : PubMed/NCBI
20.	Rasul A, Bao R, Malhi M, Zhao B, Tsuji I, Li J and Li X: Induction of apoptosis by costunolide in bladder cancer cells is mediated through ROS generation and mitochondrial dysfunction. Molecules. 18:1418–1433. 2013. View Article : Google Scholar : PubMed/NCBI
21.	Ferrari FC, Ferreira LC, Souza MR, Grabe-Guimarães A, Paula CA, Rezende SA and Saúde-Guimarães DA: Anti-inflammatory sesquiterpene lactones from Lychnophora trichocarpha Spreng. (Brazilian Arnica). Phytother Res. 27:384–389. 2013.PubMed/NCBI
22.	Kretschmer N, Rinner B, Stuendl N, et al: Effect of costunolide and dehydrocostus lactone on cell cycle, apoptosis, and ABC transporter expression in human soft tissue sarcoma cells. Planta Med. 78:1749–1756. 2012. View Article : Google Scholar : PubMed/NCBI
23.	Piornedo Rdos R, de Souza P, Stefanello ME, Strapasson RL, Zampronio AR and Kassuya CA: Anti-inflammatory activity of extracts and 11,13-dihydrozaluzanin C from Gochnatia polymorpha ssp floccosa trunk bark in mice. J Ethnopharmacol. 133:1077–1084. 2011.PubMed/NCBI
24.	Collins SJ, Ruscetti FW, Gallagher RE and Gallo RC: Terminal differentiation of human promyelocytic leukemia cells induced by dimethyl sulfoxide and other polar compounds. Proc Natl Acad Sci USA. 75:2458–2462. 1978. View Article : Google Scholar
25.	Tanaka H, Abe E, Miyaura C, Shiina Y and Suda T: 1 alpha,25-dihydroxyvitamin D3 induces differentiation of human promyelocytic leukemia cells (HL-60) into monocytemacrophages, but not into granulocytes. Biochem Biophys Res Commun. 117:86–92. 1983. View Article : Google Scholar : PubMed/NCBI
26.	Kim SH, Danilenko M and Kim TS: Differential enhancement of leukaemia cell differentiation without elevation of intracellular calcium by plant-derived sesquiterpene lactone compounds. Br J Pharmacol. 155:814–825. 2008. View Article : Google Scholar
27.	Song JH, Kim HJ, Lee CH, Kim SJ, Hwang SY and Kim TS: Identification of gene expression signatures for molecular classification in human leukemia cells. Int J Oncol. 29:57–64. 2006.PubMed/NCBI
28.	Pan Y, Chen H, Siu F and Kilberg MS: Amino acid deprivation and endoplasmic reticulum stress induce expression of multiple activating transcription factor-3 mRNA species that, when over-expressed in HepG2 cells, modulate transcription by the human asparagine synthetase promoter. J Biol Chem. 278:38402–38412. 2003. View Article : Google Scholar
29.	Rousseau J, Gagné V, Labuda M, et al: ATF5 polymorphisms influence ATF function and response to treatment in children with childhood acute lymphoblastic leukemia. Blood. 118:5883–5890. 2011. View Article : Google Scholar : PubMed/NCBI
30.	Kang SN, Kim SH, Chung SW, Lee MH, Kim HJ and Kim TS: Enhancement of 1 alpha,25-dihydroxyvitamin D(3)-induced differentiation of human leukaemia HL-60 cells into monocytes by parthenolide via inhibition of NF-kappa B activity. Br J Pharmacol. 135:1235–1244. 2002. View Article : Google Scholar : PubMed/NCBI
31.	Gutierrez JA, Pan YX, Koroniak L, Hiratake J, Kilberg MS and Richards NG: An inhibitor of human asparagine synthetase suppresses proliferation of an L-asparaginase-resistant leukemia cell line. Chem Biol. 13:1339–1347. 2006. View Article : Google Scholar : PubMed/NCBI
32.	Lorenzi PL, Reinhold WC, Rudelius M, et al: Asparagine synthetase as a causal, predictive biomarker for L-asparaginase activity in ovarian cancer cells. Mol Cancer Ther. 5:2613–2623. 2006. View Article : Google Scholar : PubMed/NCBI
33.	Clavell LA, Gelber RD, Cohen HJ, et al: Four-agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia. N Engl J Med. 315:657–663. 1986. View Article : Google Scholar : PubMed/NCBI
34.	Ortega JA, Nesbit ME Jr, Donaldson MH, Hittle RE, Weiner J, Karon M and Hammond D: L-Asparaginase, vincristine, and prednisone for induction of first remission in acute lymphocytic leukemia. Cancer Res. 37:535–540. 1977.PubMed/NCBI
35.	Hongo S, Sakagami H and Sato T: Decrease in asparagine synthetase activity during cell differentiation of mouse and human leukemia cell lines. Leukemia. 4:708–711. 1990.PubMed/NCBI
36.	Hashimoto K, Suzuki F and Sakagami H: Declined asparagine synthetase mRNA expression and enhanced sensitivity to asparaginase in HL-60 cells committed to monocytic differentiation. Anticancer Res. 29:1303–1308. 2009.PubMed/NCBI